These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 29642018)

  • 1. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence.
    de Souza CF; Sabedot TS; Malta TM; Stetson L; Morozova O; Sokolov A; Laird PW; Wiznerowicz M; Iavarone A; Snyder J; deCarvalho A; Sanborn Z; McDonald KL; Friedman WA; Tirapelli D; Poisson L; Mikkelsen T; Carlotti CG; Kalkanis S; Zenklusen J; Salama SR; Barnholtz-Sloan JS; Noushmehr H
    Cell Rep; 2018 Apr; 23(2):637-651. PubMed ID: 29642018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular subtypes of glioma identified by genome-wide methylation profiling.
    Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
    Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
    Turcan S; Rohle D; Goenka A; Walsh LA; Fang F; Yilmaz E; Campos C; Fabius AW; Lu C; Ward PS; Thompson CB; Kaufman A; Guryanova O; Levine R; Heguy A; Viale A; Morris LG; Huse JT; Mellinghoff IK; Chan TA
    Nature; 2012 Feb; 483(7390):479-83. PubMed ID: 22343889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
    Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H
    Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.
    Wiestler B; Capper D; Sill M; Jones DT; Hovestadt V; Sturm D; Koelsche C; Bertoni A; Schweizer L; Korshunov A; Weiß EK; Schliesser MG; Radbruch A; Herold-Mende C; Roth P; Unterberg A; Hartmann C; Pietsch T; Reifenberger G; Lichter P; Radlwimmer B; Platten M; Pfister SM; von Deimling A; Weller M; Wick W
    Acta Neuropathol; 2014 Oct; 128(4):561-71. PubMed ID: 25008768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA demethylation is associated with malignant progression of lower-grade gliomas.
    Nomura M; Saito K; Aihara K; Nagae G; Yamamoto S; Tatsuno K; Ueda H; Fukuda S; Umeda T; Tanaka S; Takayanagi S; Otani R; Nejo T; Hana T; Takahashi S; Kitagawa Y; Omata M; Higuchi F; Nakamura T; Muragaki Y; Narita Y; Nagane M; Nishikawa R; Ueki K; Saito N; Aburatani H; Mukasa A
    Sci Rep; 2019 Feb; 9(1):1903. PubMed ID: 30760837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular subtypes of glioblastoma are relevant to lower grade glioma.
    Guan X; Vengoechea J; Zheng S; Sloan AE; Chen Y; Brat DJ; O'Neill BP; de Groot J; Yust-Katz S; Yung WK; Cohen ML; Aldape KD; Rosenfeld S; Verhaak RG; Barnholtz-Sloan JS
    PLoS One; 2014; 9(3):e91216. PubMed ID: 24614622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
    Noushmehr H; Weisenberger DJ; Diefes K; Phillips HS; Pujara K; Berman BP; Pan F; Pelloski CE; Sulman EP; Bhat KP; Verhaak RG; Hoadley KA; Hayes DN; Perou CM; Schmidt HK; Ding L; Wilson RK; Van Den Berg D; Shen H; Bengtsson H; Neuvial P; Cope LM; Buckley J; Herman JG; Baylin SB; Laird PW; Aldape K;
    Cancer Cell; 2010 May; 17(5):510-22. PubMed ID: 20399149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.
    Wiestler B; Claus R; Hartlieb SA; Schliesser MG; Weiss EK; Hielscher T; Platten M; Dittmann LM; Meisner C; Felsberg J; Happold C; Simon M; Nikkhah G; Papsdorf K; Steinbach JP; Sabel M; Grimm C; Weichenhan D; Tews B; Reifenberger G; Capper D; Müller W; Plass C; Weller M; Wick W;
    Neuro Oncol; 2013 Aug; 15(8):1017-26. PubMed ID: 23595628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
    Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W
    Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
    Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
    J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.
    Li S; Chowdhury R; Liu F; Chou AP; Li T; Mody RR; Lou JJ; Chen W; Reiss J; Soto H; Prins R; Liau LM; Mischel PS; Nghiemphu PL; Yong WH; Cloughesy TF; Lai A
    Clin Cancer Res; 2014 Nov; 20(22):5808-22. PubMed ID: 25224277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.
    Mur P; Mollejo M; Ruano Y; de Lope ÁR; Fiaño C; García JF; Castresana JS; Hernández-Laín A; Rey JA; Meléndez B
    Acta Neuropathol; 2013 Aug; 126(2):277-89. PubMed ID: 23689617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
    Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
    Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications.
    Malta TM; de Souza CF; Sabedot TS; Silva TC; Mosella MS; Kalkanis SN; Snyder J; Castro AVB; Noushmehr H
    Neuro Oncol; 2018 Apr; 20(5):608-620. PubMed ID: 29036500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.
    Christensen BC; Smith AA; Zheng S; Koestler DC; Houseman EA; Marsit CJ; Wiemels JL; Nelson HH; Karagas MR; Wrensch MR; Kelsey KT; Wiencke JK
    J Natl Cancer Inst; 2011 Jan; 103(2):143-53. PubMed ID: 21163902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone H3.3 G34-mutant Diffuse Gliomas in Adults.
    Wang L; Shao L; Li H; Yao K; Duan Z; Zhi C; Song S; Cheng Y; Wang F; Wang W; Piao Y; Gui Q; Lu D; Qi X; Teng L
    Am J Surg Pathol; 2022 Feb; 46(2):249-257. PubMed ID: 34352809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma.
    Fukunaga T; Fujita Y; Kishima H; Yamashita T
    PLoS One; 2018; 13(11):e0206552. PubMed ID: 30388142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.